Pharmaceutical

Mosanna Therapeutics gains $80m to advance OSA nasal spray

Mosanna Therapeutics has secured $80m in a Series A funding round for advancing new nighttime nasal spray for obstructive sleep apnoea (OSA).

Jun 11, 2025 - 06:00
Mosanna Therapeutics gains $80m to advance OSA nasal spray
Mosanna Therapeutics has secured $80m in a Series A funding round for advancing new nighttime nasal spray for obstructive sleep apnoea (OSA).
Read the original article

Tags:

Previous Article

Odyssey bails on public listing as US IPO landscape stutters

Next Article

RFK Jr axes vaccine advisory committee members

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Can pharma overcome generative AI’s bias problem?

Can pharma overcome generative AI’s bias problem?

Apr 3, 2024

Amid the battle over abortion rights, a failure to agree on how to define abortion

Amid the battle over abortion rights, a failure to agre...

Mar 12, 2024

Listen: Racing for gene therapy, a pioneering approval, & startups in the lurch

Listen: Racing for gene therapy, a pioneering approval,...

Aug 17, 2023